Physician profile
Elizabeth E Littlejohn
NPI 1144370180
$10,159.18
in general payments reported to CMS, 2019-2025
34 companies · $5,828 in 2025
The $5,828 reported for 2025 was more than what 85% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $273 · 2021: $230 · 2022: $873 · 2023: $1,605 · 2024: $770 · 2025: $5,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,650 · Food and Beverage: $3,539 · Education: $13.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,650.00 |
| Food and Beverage | $3,538.90 |
| Education | $13.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,705.93 | 2019-2025 | |
| Dexcom, INC. | $682.43 | 2021-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $644.81 | 2019-2025 | Omnipod |
| Medtronic, INC. | $603.00 | 2022-2025 | Minimed 780g, Minimed 770g |
| Xeris Pharmaceuticals, INC. | $436.65 | 2020-2025 | Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $417.77 | 2022-2025 | Skytrofa |
| Azurity Pharmaceuticals, INC. | $313.34 | 2023-2025 | Triptodur, Triptodur |
| Medtronic Minimed, INC. | $285.22 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $283.98 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $280.97 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $272.08 | 2023-2024 | |
| Novo Nordisk INC | $209.37 | 2019-2025 | Sogroya |
| Alexion Pharmaceuticals, INC. | $183.81 | 2019-2024 | Strensiq |
| Boston Scientific Corporation | $100.10 | 2021-2023 | Eluvia |
| Ucb, INC. | $97.46 | 2024-2025 | Fintepla, Briviact |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amphastar Pharmaceuticals, INC. | $78.13 | 2024-2025 | |
| Eton Pharmaceuticals, INC. | $62.94 | 2025 | Khindivi, Increlex, Alkindi |
| Ultragenyx Pharmaceutical INC. | $56.45 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $56.11 | 2024-2025 | Bylvay |
| Arbor Pharmaceuticals, INC. | $49.18 | 2019-2020 | |
| Soleno Therapeutics, INC. | $39.99 | 2025 | Vykat Xr |
| 180 Medical, INC. | $37.77 | 2023-2025 | |
| Lilly USA, LLC | $37.03 | 2019-2020 | |
| Tolmar, INC. | $35.43 | 2023-2025 | Fensolvi |
| Phadia US INC. | $25.25 | 2019-2020 | |
| Beta Bionics, INC. | $21.37 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $21.14 | 2025 | Twiist |
| Endo Pharmaceuticals INC. | $20.57 | 2021 | |
| Biomarin Pharmaceutical INC. | $19.83 | 2023 | Voxzogo 1.2mg |
| Qol Medical, LLC | $19.12 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.95 | 2024 | Eohilia |
| Amneal Pharmaceuticals LLC | $16.04 | 2023 | Unithroid |
| Ferring Pharmaceuticals INC. | $15.41 | 2019 | |
| Mirum Pharmaceuticals, INC. | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Littlejohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.